| Document |
Document Title |
|
WO/1997/037953A1 |
The insertion of isotopically labeled portions into solid state combinatorial synthesis constructs followed by mass spectrometer, mass-based nuclear magnetic resonance spectrometry or mass-based infrared spectrometry analysis allows for ...
|
|
WO/1997/021730A1 |
Human, swine and rat growth hormone secretagogue receptors have been isolated, cloned and sequenced. Growth hormone secretagogue receptors are new members of the G-protein family of receptors. The growth hormone secretagogue receptors ma...
|
|
WO/1997/021674A1 |
The invention relates to the trans isomer of 4-iodotamoxifenaziridine and particularly when it is marked by a radioactive isotope of iodine, more particularly iodine 125. The invention also relates to the preparation of said pure trans i...
|
|
WO/1997/017092A1 |
The invention provides novel amino acid compounds of use in detecting and evaluating brain and body tumors. These compounds combine the advantageous properties of 1-amino-cycloalkyl-1-carboxylic acids, namely, their rapid uptake and prol...
|
|
WO/1997/012850A2 |
New compounds have the general formula (I): M - L, in which M stands for a radio-isotope of Tc or Re and L stands for a ligand having the general formula (II): B-CR1R2-(CR3R4)n=1,2-S-CHR5-CHR6-SO2-NH-CR7R8-(CR9R10)m=1,2-
D, in which R1, ...
|
|
WO/1997/012636A2 |
The invention concerns novel compounds of general formula (I), M-L, in which M stands for a radioisotope of Tc or Re and L stands for a ligand of general formula (II) R1S-CR2R3-(CR4R5)n=1,2-S-CHR6-CHR7-SO2-NH-(CR8R9)m=1,2-CO-B in which R...
|
|
WO/1997/010852A2 |
The invention pertains to novel compounds of the general formula (I): M - L in which M stands for a radioisotope of Tc or Re, L stands for a ligand of the general formula (II): B-CO-(CR1R2)n=1,2-S-CHR3-CHR4-SO2-NH-CR5R6-(CR7R8)m=1,2-SR9 ...
|
|
WO/1997/003042A1 |
2,2-dideutero-5-aminolevulinic acid, or salts, hydrates or solvates thereof (preferably 2,2-dideutero-5-aminolevulinic acid hydrochloride), and a process for producing 2,2-dideutero-5-aminolevulinic acid. This acid is useful as a contras...
|
|
WO/1997/002246A1 |
A compound is provided of formula (I) wherein n is 4-16, Det is an organic group comprising a radioisotope or capable of chelating a radioisotope, and Z- is one equivalent of a biologically acceptable anion, which compounds are useful to...
|
|
WO/1997/001520A1 |
A stabilized composition comprising an organic compound labeled with a 'beta'-emitting radionuclide and a stabilizing effective amount of a non-radiolabeled stabilizing compound selected from the group consisting of (i) heteroaryls havin...
|
|
WO/1996/040637A1 |
This invention provides novel reagents for the preparation of radiopharmaceuticals useful as imaging agents for the diagnosis of cardiovascular disorders, infection, inflammation and cancer, diagnostic kits comprising said reagents and i...
|
|
WO/1996/040616A1 |
The synthesis of tamoxifen derivatives, most particularly halo, halo alkyl, hydroxy, amino tamoxifen derivatives is disclosed. The native tamoxifen molecule includes a substituted chemical group positioned on the aliphatic chain of the t...
|
|
WO/1996/036367A1 |
A method is provided for enhancing transmembrane transport of a diagnostic agent across a membrane of a living cell. The method comprises contacting a membrane of a living cell with a complex formed between said diagnostic agent and liga...
|
|
WO/1996/032968A1 |
The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastoma...
|
|
WO/1996/031243A1 |
This invention provides novel radiopharmaceuticals which are useful as imaging agents for the diagnosis of cardiovascular disorders, infectious diseases and cancer. The radiopharmaceuticals are comprised of phosphine or arsine ligated te...
|
|
WO/1996/030055A2 |
This invention relates to radiotherapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic and radiotherapeutic agents. Specifically, the invention relates to vasoactive int...
|
|
WO/1996/022297A1 |
A phosphorus ester oligomer having structure (I) wherein A can be the same or different in each monomeric unit and each is independently selected from the group consisting of oxygen, sulfur, lower alkyl, alkyl- or aryl-substituted amino ...
|
|
WO/1996/020913A1 |
Novel trienoic retinoid compounds having activity for retinoic acid receptors and retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such compounds and methods for their use.
|
|
WO/1996/020928A1 |
Compounds of formula (I) or pharmaceutically acceptable salts therof wherein X = O, CO or CHOH; R' is fluoroalkyl of 2 to 5 carbon atoms and 1 to 11 fluorine atoms; mono- and di-substituted benzyl wherein the substituents are selected fr...
|
|
WO/1996/020940A1 |
The invention relates to a novel chemical compound having structural formula (I). The compound (I) is useful in the diagnosis of dopaminergic diseases like Parkinson's disease and schizophrenia. The invention also relates to mixtures of ...
|
|
WO/1996/018650A1 |
A receptor in substantially pure form obtainable from rat forebrain tissue which is characterised in that: a) compound A binds to it with a Kd of 40nM for rat forebrain tissue, b) compound A binds to it with a Bmax of 220 pmol/g protein ...
|
|
WO/1996/015086A1 |
The present invention discloses a method and an apparatus for high yield production of 11C-methyl iodide by selectively monohalogenating 11C-methane, whereby the method is comprising a first step of introducing 11CH4 into an apparatus co...
|
|
WO/1996/014277A1 |
This invention provides a novel compound for 35S-labelling oligonucleotides. The compound is 35S-3H-1,2-benzodithiol-3-one-1,1 dioxide (1). In Structure (I), the asterisk indicates the position of the 35S. Also provided is a method of sy...
|
|
WO/1996/004288A1 |
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotropic lateral sclerosis, Huntingto...
|
|
WO/1996/003124A1 |
Non-naturally occurring dynemicin analogs are provided, which are useful as DNA cleaving agents, cytotoxic agents, and/or anti-tumor compounds. Methods of making dynemicin analogs are also provided.
|
|
WO/1996/002500A1 |
The invention relates to novel chelate formers containing sulphonamide groups and their metallic chelates of general formula (I) in which n, m, p, V1, V2, V3, V4, X1, X2, X3, R1, R2, R3 and R4 have different meanings, pharmaceutical agen...
|
|
WO/1995/034315A1 |
Radiolabeled annexin-galactors conjugates useful for imaging vascular trombi are discussed. Methods for making such radiolabeled annexin-galactose conjugates are also addressed.
|
|
WO/1995/033495A1 |
A method of radiolabeling a protein with a radionuclide including contacting the protein with a protected tertiary thiol-containing bifunctional chelating agent that is capable of reacting with the protein at one end of the agent and is ...
|
|
WO/1995/032192A1 |
The present invention provides aromatic amine substituted metal chelating compounds of formula (I) in which the variables are as defined in the claims, chelates and chelate-targeting moiety conjugates formed from the chelating compounds,...
|
|
WO/1995/031221A1 |
This invention relates to diagnostic and radiodiagnostic agents, including radiolabeled scintigraphic imaging agents, and therapeutic and radiotherapeutic agents. The invention provides such agents and reagents for preparing such agents,...
|
|
WO/1995/029925A1 |
A compound consisting essentially of a multidentade ligand including at least two thioether groups for being complexed to Rhodium-105 in specific activities that are sufficiently high for use in formulating therapeutic 105Rh-radiopharmac...
|
|
WO/1995/029669A2 |
A compound and method of making a compound for use as a diagnostic or therapeutic pharmaceutical comprises either a phosphorous or germanium core and at least two hydrazine groups forming a ligand for bonding to a metal extending from th...
|
|
WO/1995/029180A1 |
Compounds of formula (1) and the metalated forms and salts thereof; wherein n is an integer of 1-4; and wherein each Pi is independently a pyrrole residue of formula (II), wherein each Ria and Rib is independently a noninterfering substi...
|
|
WO/1995/027701A1 |
Metal-containing steroid mimic complexes are provided. Compositions containing a metal ion incorporated into a steroid skeleton structure and ligands useful in the preparation of such compositions are also provided. The metal ion is pref...
|
|
WO/1995/026325A2 |
A method of enhancing the efficiency and increasing the duration of action of drugs (e.g. dihydropyridines) and particularly of nifedipine wherein one or more hydrogen atoms are deuterated and wherein the deuterated nifedipine has unexpe...
|
|
WO/1995/020580A1 |
The invention concerns macrocyclic octaaza compounds of general formula (I), in which A, D, W, X, R1, R2, R3 and R4 are various groups, their metal complexes, agents containing such complexes and their use in medical diagnosis and therap...
|
|
WO/1995/019338A1 |
Novel compounds of formula (I) and novel complexes of these compounds with metals are useful in diagnostic and therapeutic methods, wherein R, R* an Q have the meanings given in the description and one of G, and G2 is -N(R2)2, the other ...
|
|
WO/1995/018668A1 |
Ionisable or polarisable, carrier-free radionuclides may be separated by electrofixation, in a manner that is particularly well adapted to practical requirements, from a low electric conductivity liquid target material in a flow cell (1)...
|
|
WO/1995/011080A1 |
Synthesis of small quantities of compounds such as methanol from reagents, especially radio-labelled reagents such as 11C oxides, in a carrier gas by a catalytic reaction using a catalyst that has been pre-conditioned for the reaction by...
|
|
WO/1995/011217A1 |
Isotopically-labeled retinoids, methods for their synthesis, and their use in the discovery of Retinoid X Receptor ligands are provided. Use of the isotopically-labeled retinoids in mass spectral metabolism studies are also provided.
|
|
WO/1995/009844A1 |
The present invention involves a rapid synthesis of 18 F-FMISO and analogs thereof. New precursors such as 1-(2'-nitro-1'-imidazolyl)-2-O-acetyl-3-O-tosylpropanol, glycerol-1,3-ditosylate-2-O-acetylate, 1-(2'-nitro-1'-imidazolyl)-2,3-O-d...
|
|
WO/1995/005398A1 |
Novel chelating compounds and the corresponding radionuclide metal chelates are useful for radiolabeling proteins such as antibodies, ligands such as biotin and anti-ligands such as streptavidin with radionuclide metals such as 99mTc, 18...
|
|
WO/1995/004552A2 |
The invention concerns ligands, e.g. based on alkylene amine oxime particularly butylene amine oxime ring structures, and radiometal complexes thereof. The radiometal complexes are intrinsically capable of localising in tumours or hypoxi...
|
|
WO/1995/004114A1 |
Tris(isonitrile)copper(I) sulfate complexes and their use in synthetic methods for making radionuclide isonitrile coordination complexes such as [99mTc(1-isocyano-2-methoxy-2-methylpropane)6]+. The coordination complexes are useful as ra...
|
|
WO/1995/004018A1 |
Methods for the synthesis of 9-cis monotritium-labeled retinoids, and their use in the discovery of Retinoid X Receptor ligands are provided. In addition, 9-cis monotritium-labeled retinoids, as well as novel intermediates and tritium-la...
|
|
WO/1995/003280A1 |
Radionuclide chelating compounds are provided for conjugation to targeting molecules such as proteins, peptides or antibodies. The resulting labelled targeting molecules may be used in diagnosis and therapy.
|
|
WO/1995/002587A1 |
Compounds of formula (I) are oxytocin antagonists useful in the treatment of preterm labor, dysmenorrhea and for the stoppage of labor preparatory to ceasarean delivery.
|
|
WO/1995/002423A1 |
Protein, ligand and anti-ligand conjugated chelated metal radionuclides are provided for use in vivo. Intermediates are provided for preparing the compositions efficiently.
|
|
WO/1994/028943A1 |
Analogs of cytochalasin B are used as radiopharmaceuticals to provide an image for the nuclear imaging of glucose transport across cell membranes. Like cytochalasin B, the analogs bind specifically to glucose transport protein, and in do...
|
|
WO/1994/026314A1 |
The present invention relates to compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds also bind wi...
|
